Mode of action of the lanthionine-containing peptide antibiotics duramycin, duramycin B (cas 132246-31-2) and C, and cinnamycin as indirect inhibitors of phospholipase A2
-
Add time:08/10/2019 Source:sciencedirect.com
Effects of the lanthionine-containing peptide antibiotics duramycin, duramycin B (cas 132246-31-2), duramycin C and cinnamycin on the activity of phospholipase A2 from six different sources were studied, and their mode of action was investigated. The four antibiotics inhibited potently all tested phospholipases A2, with IC50 values of around 1 μM, using phosphatidylethanolamine or [1-14C]oleate-labelled Escherichia coli, whose phospholipids are rich in phosphatidylethanolamine, as substrates. No inhibition was observed when the substrate was phosphatidylcholine. Binding of the antibiotics to the lipid fraction of E. coli could be demonstrated by co-sedimentation with whole, but not with lipid-depleted E. coli. In addition, preincubation of duramycin B with vesicles of phosphatidylethanolamine, but not those of phosphatidylcholine, prevented the inhibition of phospholipase A2 activity. The interaction of duramycin B and C, but not that of the biologically inactive compounds actagardine and the duramycin B trisulphoxide, with phosphatidylethanolamine was demonstrated using circular dichroism studies. On the other hand, no interaction of duramycin B with phosphatidylcholine could be demonstrated. A strict correlation between the physico-chemical interaction of the studied lantibiotics, demonstrated by circular dichroism spectroscopy, and their inhibition of phospholipase A2 was observed. These results suggest that lanthionine-containing peptide antibiotics inhibit phospholipase A2 indirectly by specifically sequestering the substrate phosphatidylethanolamine. This mode of action is analogous to the one described for the protein lipocortin.
We also recommend Trading Suppliers and Manufacturers of duramycin B (cas 132246-31-2). Pls Click Website Link as below: cas 132246-31-2 suppliers
Prev:The feasibility of imaging myocardial ischemic/reperfusion injury using 99mTc-labeled duramycin in a porcine model
Next:Imaging of rat cerebral ischemia-reperfusion injury using99mTc-labeled duramycin) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Imaging of rat cerebral ischemia-reperfusion injury using99mTc-labeled duramycin08/11/2019
- The feasibility of imaging myocardial ischemic/reperfusion injury using 99mTc-labeled duramycin in a porcine model08/09/2019
- A single-step kit formulation for the 99mTc-labeling of HYNIC-Duramycin08/08/2019
- Understanding the in vivo uptake kinetics of a phosphatidylethanolamine-binding agent 99mTc-Duramycin08/07/2019
- Molecular Imaging of Apoptosis in Ischemia Reperfusion Injury With Radiolabeled Duramycin Targeting Phosphatidylethanolamine08/06/2019
- Duramycin-porphyrin conjugates for targeting of tumour cells using photodynamic therapy08/05/2019
- Detection of atherosclerotic plaques in ApoE-deficient mice using 99mTc-duramycin08/04/2019
- [99mTc]duramycin for cell death imaging: Impact of kit formulation, purification and species difference08/03/2019
- [99mTc]Tc-duramycin, a potential molecular probe for early prediction of tumor response after chemotherapy08/02/2019


